Abstract: |
Ovarian malignancies are a leading cause of death in women in the United States and a significant health issue for women worldwide. Anatomic imaging with ultrasound, computed tomography, and magnetic resonance is a main tool for the diagnosis, staging, and follow-up of recurrent disease; however, it lacks biologic information. Nuclear imaging, primarily positron emission tomography (PET) with 2- deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), has been increasingly used for the detection of cancer. Encouraging data have emerged in recent years that support the use of [18F]FDG PET in a variety of clinical settings in ovarian cancer management. © Springer International Publishing Switzerland 2017. All rights reserved. |